Free Trial
NASDAQ:FHTX

Foghorn Therapeutics (FHTX) Stock Price, News & Analysis

Foghorn Therapeutics logo
$6.13 +0.03 (+0.49%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$6.14 +0.01 (+0.16%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Foghorn Therapeutics Stock (NASDAQ:FHTX)

Key Stats

Today's Range
$5.96
$6.20
50-Day Range
$4.05
$6.13
52-Week Range
$2.94
$10.25
Volume
148,403 shs
Average Volume
143,822 shs
Market Capitalization
$341.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.13
Consensus Rating
Buy

Company Overview

Foghorn Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

FHTX MarketRank™: 

Foghorn Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 784th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Foghorn Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Foghorn Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Foghorn Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Foghorn Therapeutics are expected to grow in the coming year, from ($1.55) to ($1.02) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Foghorn Therapeutics is -4.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Foghorn Therapeutics is -4.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Foghorn Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.70% of the float of Foghorn Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Foghorn Therapeutics has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Foghorn Therapeutics has recently increased by 8.16%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Foghorn Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Foghorn Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.70% of the float of Foghorn Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Foghorn Therapeutics has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Foghorn Therapeutics has recently increased by 8.16%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    1 people have searched for FHTX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Foghorn Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.58% of the stock of Foghorn Therapeutics is held by insiders.

  • Percentage Held by Institutions

    61.55% of the stock of Foghorn Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Foghorn Therapeutics' insider trading history.
Receive FHTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Foghorn Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FHTX Stock News Headlines

Foghorn Therapeutics Inc (FHTX) - Investing.com
The big winner of Crypto week?
It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bitcoin hitting $123,000 and giants like BlackRock and Fidelity pouring in, one expert believes a lesser-known coin could soon be vaulted to the top — possibly even landing in the government’s digital reserve.
See More Headlines

FHTX Stock Analysis - Frequently Asked Questions

Foghorn Therapeutics' stock was trading at $4.72 at the beginning of the year. Since then, FHTX stock has increased by 29.9% and is now trading at $6.13.

Foghorn Therapeutics Inc. (NASDAQ:FHTX) released its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.30) earnings per share for the quarter, meeting the consensus estimate of ($0.30). The firm had revenue of $5.95 million for the quarter, compared to analyst estimates of $4.96 million.

Foghorn Therapeutics (FHTX) raised $120 million in an initial public offering (IPO) on Friday, October 23rd 2020. The company issued 7,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Shares of FHTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Foghorn Therapeutics investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), NVIDIA (NVDA), Netflix (NFLX), Meta Platforms (META) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/14/2025
Today
7/20/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FHTX
CIK
1822462
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$9.00
Potential Upside/Downside
+97.8%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$86.62 million
Net Margins
-342.23%
Pretax Margin
-342.23%
Return on Equity
N/A
Return on Assets
-27.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.16
Quick Ratio
3.16

Sales & Book Value

Annual Sales
$23.50 million
Price / Sales
14.54
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.82) per share
Price / Book
-7.48

Miscellaneous

Outstanding Shares
55,741,000
Free Float
51,516,000
Market Cap
$341.69 million
Optionable
Optionable
Beta
3.05

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:FHTX) was last updated on 7/20/2025 by MarketBeat.com Staff
From Our Partners